The 2026 FDA peptide review.

On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will hold its first formal review of peptide bulk drug substances since 2023. The meeting is scheduled to address seven compounds currently restricted under Category 2 of the 503A bulks list — meaning they cannot be compounded for office use or routine dispensing, and most outsourcing facilities have stopped supplying them.

For anyone tracking the longevity-medicine space, this is the regulatory event of the year. The composition of the list, the committee’s recommendations, and the FDA’s subsequent rulemaking will determine which peptides remain practically accessible through legitimate compounding channels — and which get pushed into research-only or grey-market status.

The seven peptides under review

The agenda has not been finalized in writing, but the docket and public-comment record point to the following compounds being on the list:

• BPC-157 — gastric protective peptide; widely used off-label for soft-tissue recovery.
• TB-500 (Thymosin Beta-4 fragment) — companion to BPC-157 in many recovery protocols.
• KPV — anti-inflammatory tripeptide, alpha-MSH fragment.
• Epitalon — pineal-gland tetrapeptide; under longevity research for telomerase activity.
• CJC-1295 / Ipamorelin — growth-hormone secretagogues, frequently combined.
• Selank — anxiolytic regulatory peptide.

What the categories actually mean

Category 1

Bulk drug substances that may be used in compounding under section 503A. A 503A pharmacy can compound these for an individual patient with a valid prescription. This is the practical regulatory home for everything you’d want a longevity provider to be able to prescribe.

Category 2

Substances under formal FDA review with significant safety risks — compounding effectively prohibited until reclassified. Most of the peptides above sit here today.

Category 3

Substances the FDA has already determined should not be compounded. Functionally a permanent ban. None of the peptides under review are currently in Category 3, and the worst-case PCAC outcome is retention in Category 2 — not promotion to Category 3.

What we expect

The pre-meeting comment record is unusually well-developed for a PCAC docket. Industry submissions from major outsourcing facilities, physician groups, and patient advocates have all filed in favor of Category 1 reclassification for at least four of the seven compounds — most strongly for BPC-157 and KPV, which have the cleanest safety record.

Our read of the submitted evidence:

• Likely to move to Category 1: KPV, BPC-157, TB-500. Strong safety data, established compounding history, patient demand documented.
• Plausible but uncertain: CJC-1295 / Ipamorelin. The pharmacology is well-characterized but the GH-axis modulation will draw closer scrutiny.
• Most likely to stay in Category 2: Epitalon, Selank. Less U.S. clinical history; the FDA tends to be conservative when the evidence base is predominantly non-U.S.

These are predictions, not commitments. The committee can — and does — surprise.

Reclassification doesn’t make a compound “FDA-approved.” It makes it legally compoundable. The distinction matters because most peptide pharmacology is done at the compounding tier, not the branded-drug tier.Halo regulatory desk

Timeline after the meeting

PCAC is advisory. After the July 23–24 meeting, the FDA evaluates the recommendations and issues either an interim policy or a proposed rule. Historical pattern:

• Q4 2026: FDA notice of proposed action, with a comment period.
• Q1–Q2 2027: Final rule. Peptides moved to Category 1 become legally compoundable nationwide.
• Q2–Q3 2027: Outsourcing facilities resume bulk supply; compounding pharmacies bring formulations back online.

For members on existing peptide protocols, nothing changes immediately. Patient-specific compounding under a valid prescription is unaffected by the review until the FDA acts on PCAC’s recommendations. We will publish a follow-up brief after the meeting concludes.

How Halo is positioning

We’ve built our peptide program assuming the conservative outcome — that BPC-157 and KPV move to Category 1, that the GH-secretagogues stay restricted longer, and that Epitalon remains outside the formal channel for now. Members who started a protocol under the current regime have been onboarded with that timeline in mind.

If the meeting outcome is more favorable, the program expands. If it’s less favorable than we expect, we already have substitutions mapped that don’t depend on Category 2 compounds. The protocol is built to survive the regulatory outcome — not to bet on it.